Format

Send to

Choose Destination
Biomark Med. 2019 Jun;13(9):761-771. doi: 10.2217/bmm-2018-0441. Epub 2019 Jun 3.

Expression of p16 and p53 in non-small-cell lung cancer: clinicopathological correlation and potential prognostic impact.

Author information

1
Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, PR China.
2
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA.
3
Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA.
4
Department of Pathology, School of Basic Medical Science, Hangzhou Medical College, Hangzhou 310053, PR China.

Abstract

Aim: p16 and p53 are frequently altered intracellular pathways in cancers. We investigated the aberrant expression of p16 and its relationship with p53 and HPV status in primary non-small-cell lung carcinoma. Patients & methods: Lung tumor tissue microarray (n = 163), immunohistochemical study of p16 and p53, and HPV in-situ hybridization were analyzed. Results: p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88). HPV was detected in 16 and 10.2% of ADC and squamous cell carcinoma. In ADCs, p16 positive tumors demonstrated a favorable median overall survival time of 60.9 months, compared with p16 negative tumors of 46.9 months (p < 0.05). Furthermore, we did not find significant relationships between p16 expression and HPV status, nor with p53 expression. Conclusion: p16 play an unique role in lung cancer survival. The mechanism of p16 needs to be further studied.

KEYWORDS:

hybridization; HPV; adenocarcinomas; biomarker; clinical survival; human papilloma virus; immunohistochemistry; non-small-cell lung carcinoma; p16; p53; squamous cell carcinomas

PMID:
31157548
DOI:
10.2217/bmm-2018-0441

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center